[go: up one dir, main page]

PE20080855A1 - Derivados de pirazina-2-carboxamida - Google Patents

Derivados de pirazina-2-carboxamida

Info

Publication number
PE20080855A1
PE20080855A1 PE2007001334A PE2007001334A PE20080855A1 PE 20080855 A1 PE20080855 A1 PE 20080855A1 PE 2007001334 A PE2007001334 A PE 2007001334A PE 2007001334 A PE2007001334 A PE 2007001334A PE 20080855 A1 PE20080855 A1 PE 20080855A1
Authority
PE
Peru
Prior art keywords
pirazine
amino
methyl
compounds
carboxamide
Prior art date
Application number
PE2007001334A
Other languages
English (en)
Inventor
Michel Dietz
Sabine Gruener
Sylvie C Meyer
Matthias Heinrich Nettekoven
Paul Hebeisen
Bernd Puellmann
Stephan Roever
Christoph Ullmer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39166552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080855(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20080855A1 publication Critical patent/PE20080855A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRAZINA-2-CARBOXAMIDA DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C7), HIDROXIALQUILO(C1-C7), CICLOALQUILO(C3-C7) OPCIONALMENTE SUSTITUIDO CON OH, ALCOXI(C1-C7) O HIDROXIALQUILO(C1-C7), ENTRE OTROS; R2 ES H; O R1 Y R2 JUNTO CON EL N AL QUE ESTAN UNIDOS FORMAN UN ANILLO HETEROCICLICO DE 4 A 7 MIEMBROS; R3 Y R4 SON CADA UNO ALQUIL(C1-C7)AMINO, DIALQUILO(C1-C7)AMINO, CICLOALQUIL(C3-C7)AMINO, HALOGENOFENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (3-METIL-BUTIL)-AMIDA DEL ACIDO 6-CICLOBUTILMETOXI-5-PIRROLIDIN-1-IL-PIRAZINA-2-CARBOXILICO, (6-CICLOPENTILMETOXI-5-PIRROLIDIN-1-IL-PIRAZIN-2-IL)-PIPERIDIN-1-IL-METANONA, CICLOHEXILAMIDA DEL ACIDO 6-CICLOPROPILMETOXI-5-PIRROLIDIN-1-IL-PIRAZINA-2-CARBOXILICO, 2-{[6-(4-CLORO-FENIL)-5-CICLOPROPILMETOXI-PIRAZINA-2-CARBONIL]-AMINO}-2-METIL-PROPIONATO DE METILO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES CANABINOIDES 2 (CB2) SIENDO UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, PSORIASIS, ALERGIA, ASMA, ATEROSCLEROSIS
PE2007001334A 2006-10-04 2007-10-03 Derivados de pirazina-2-carboxamida PE20080855A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121749 2006-10-04

Publications (1)

Publication Number Publication Date
PE20080855A1 true PE20080855A1 (es) 2008-06-28

Family

ID=39166552

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001334A PE20080855A1 (es) 2006-10-04 2007-10-03 Derivados de pirazina-2-carboxamida

Country Status (18)

Country Link
US (1) US7691863B2 (es)
EP (1) EP2076499B1 (es)
JP (1) JP5064506B2 (es)
KR (1) KR101114704B1 (es)
CN (1) CN101522644B (es)
AR (1) AR063101A1 (es)
AT (1) ATE467622T1 (es)
AU (1) AU2007304363B2 (es)
BR (1) BRPI0717822A2 (es)
CA (1) CA2664621A1 (es)
CL (1) CL2007002834A1 (es)
DE (1) DE602007006531D1 (es)
ES (1) ES2344128T3 (es)
IL (1) IL197763A0 (es)
MX (1) MX2009003316A (es)
PE (1) PE20080855A1 (es)
TW (1) TW200825065A (es)
WO (1) WO2008040649A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
BRPI0717845A2 (pt) * 2006-10-04 2015-06-16 Hoffmann La Roche Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
US7897621B2 (en) 2008-03-31 2011-03-01 Hoffmann-La Roche Inc. 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents
US8088920B2 (en) 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
CA2885987A1 (en) * 2012-12-07 2014-06-12 F. Hoffmann-La Roche Ag Pyridine-2-amides useful as cb2 agonists
SG10201800170YA (en) * 2012-12-07 2018-02-27 Hoffmann La Roche Novel pyridine derivatives
RS55951B1 (sr) * 2012-12-07 2017-09-29 Hoffmann La Roche Derivati pirazina kao agonisti cb2 receptora
MX2015007156A (es) * 2012-12-07 2015-10-14 Hoffmann La Roche Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2).
CR20160459A (es) * 2014-04-04 2016-12-02 Eidgenoessische Technische Hochschule Zuerich Nuevos derivados de piridina
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
KR102317480B1 (ko) 2017-03-23 2021-10-25 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN109384734B (zh) * 2017-08-14 2023-04-11 上海科胜药物研发有限公司 一种塞尔西帕中间体的制备方法
CN112074513B (zh) * 2018-06-27 2024-06-14 豪夫迈·罗氏有限公司 作为优先大麻素2激动剂的吡啶和吡嗪衍生物
EP3995155A1 (en) 2018-06-27 2022-05-11 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
BR112020025013A2 (pt) * 2018-06-27 2021-03-23 F. Hoffmann-La Roche Ag novos compostos de piridina e pirazina como inibidores do receptor 2 de canabinoide
EP3814328A1 (en) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
WO2023082145A1 (en) * 2021-11-11 2023-05-19 4B Technologies (Suzhou) Limited Intermediate compound of quinoxaline and preparation process thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5738778A (en) * 1980-08-18 1982-03-03 Kyowa Gas Chem Ind Co Ltd Novel cyanopyrazine derivative
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
EP1608373A4 (en) * 2003-03-19 2010-09-29 Exelixis Inc TIE-2 MODULATORS AND USE METHOD
WO2004111033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
GB0402357D0 (en) 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
RU2404164C2 (ru) 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives

Also Published As

Publication number Publication date
US7691863B2 (en) 2010-04-06
AU2007304363A1 (en) 2008-04-10
EP2076499A2 (en) 2009-07-08
CN101522644B (zh) 2013-04-24
DE602007006531D1 (de) 2010-06-24
AU2007304363B2 (en) 2013-01-17
EP2076499B1 (en) 2010-05-12
ES2344128T3 (es) 2010-08-18
CA2664621A1 (en) 2008-04-10
BRPI0717822A2 (pt) 2013-11-12
KR20090084842A (ko) 2009-08-05
CN101522644A (zh) 2009-09-02
WO2008040649A2 (en) 2008-04-10
KR101114704B1 (ko) 2012-03-14
MX2009003316A (es) 2009-04-09
JP2010505788A (ja) 2010-02-25
AR063101A1 (es) 2008-12-30
JP5064506B2 (ja) 2012-10-31
US20080085905A1 (en) 2008-04-10
WO2008040649A3 (en) 2008-05-29
TW200825065A (en) 2008-06-16
ATE467622T1 (de) 2010-05-15
CL2007002834A1 (es) 2008-05-16
IL197763A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
PE20080855A1 (es) Derivados de pirazina-2-carboxamida
PE20210040A1 (es) Moduladores de la via de estres integrada
PE20160869A1 (es) Derivados novedosos de amino pirimidina
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
PE20120081A1 (es) Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
ES2570784T3 (es) Piridinas sustituidas como bloqueadores de los canales de sodio
PE20130155A1 (es) Derivados de ariletinilo
PE20141582A1 (es) Pirimidinas anilladas sustituidas y uso de las mismas
PE20160431A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
AR071187A1 (es) Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
MX2011013884A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
EA201791271A1 (ru) ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
PE20090886A1 (es) Nuevos inhibidores de quinasa
ES2655391T3 (es) Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
AR082885A1 (es) Compuestos y composiciones para la inhibicion de nampt
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
AR111756A1 (es) 4-difluorometilbenzoilamidas de acción herbicida
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20120135A1 (es) Piperidinas sustituidas como antagonistas de ccr3
PE20131343A1 (es) Derivados de acido benzoico

Legal Events

Date Code Title Description
FD Application declared void or lapsed